ModraDoc006/r in Patients With Breast Cancer

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-11-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticbrainmricarcinomaline
  Phrases that lowered it: breast cancerevaluate theto evaluatepatienttolerability
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 11.7% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 20237 (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 45098 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 79.0% (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Extended Use of ModraDoc006/r NCT03150368 · started 2017 · scored riskier than 33% of active trials completed
• ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer NCT03136640 · started 2017 · scored riskier than 24% of active trials completed
• ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer NCT04028388 · started 2019 · scored riskier than 61% of active trials completed
• Food Effect Study of ModraDoc006 in Combination With Ritonavir NCT03147378 · started 2017 · scored riskier than 18% of active trials completed
• Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) NCT01295632 · started 2011 · scored riskier than 53% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.